Kiora Pharmaceuticals
KPRX
23 hedge funds and large institutions have $7.87M invested in Kiora Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
4,833% more capital invested
Capital invested by funds: $160K → $7.87M (+$7.71M)
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
53% more funds holding
Funds holding: 15 → 23 (+8)
4.28% more ownership
Funds ownership: 0.44% → 4.72% (+4.3%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.43M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$1.43M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.37M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.18M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$683K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$49.1K |
| 2 |
VF
Virtu Financial
New York
|
-$11.3K |
| 3 |
Renaissance Technologies
New York
|
-$1.27K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.15K |
| 5 |
Morgan Stanley
New York
|
-$6 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| – | -$1.15K | -246 | Closed |
|
KPRX Hedge Fund Activity: Q1 2024 in Review
23 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2024, worth a combined $7.87M — up 4,833% from $160K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new KPRX positions and 2 closed out — a net gain of 8 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $1.43M. The largest seller was Citadel Advisors, exiting entirely with an estimated $49.1K sold.
- 23 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2024, up from 15 in Q4 2023.
- Funds reported $7.87M of Kiora Pharmaceuticals stock for Q1 2024, up 4,833% quarter-over-quarter.
- 10 funds opened new Kiora Pharmaceuticals positions in Q1 2024 and 2 closed out, a net change of +8 holders.
- The largest Kiora Pharmaceuticals buyer in Q1 2024 was AIGH Capital Management, an estimated $1.43M added.
- The largest Kiora Pharmaceuticals seller in Q1 2024 was Citadel Advisors, an estimated $49.1K sold.
Based on aggregated 13F filings for Q1 2024.